Can Humanized Mice Predict Drug "behavior" in Humans?

Annual Review of Pharmacology and Toxicology

Volumn 56, Issue , 2016, Pages 323-338

  Xu, Dan ^a   Peltz, Gary ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chimeric mice; Drug metabolism; Liver humanization; Predictive toxicology

Indexed keywords

BOSENTAN; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; FIALURIDINE; MESSENGER RNA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2;

ANATOMY; ARTICLE; DRUG DISPOSITION; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG SCREENING; GENE EXPRESSION; GENE INACTIVATION; HUMAN; LIVER CELL; LIVER TOXICITY; MOUSE MODEL; NONHUMAN; PERSONALIZED MEDICINE; PHARMACODYNAMICS; PHARMACOGENETICS; PRIORITY JOURNAL; TOXIC HEPATITIS; ANIMAL; CHIMERA; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; LIVER; MOUSE; PHYSIOLOGY; PRECLINICAL STUDY; PROCEDURES;

ANIMALS; CHIMERA; DRUG EVALUATION, PRECLINICAL; DRUG-INDUCED LIVER INJURY; HUMANS; LIVER; MICE;

EID: 84954111235     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010715-103644     Document Type: Article

References (62)

1. HardingA. 2004. More compounds failingPhase I. The Scientist, Sept. 13. http://www. The-scientist. com/articles. view/articleNo/15910/title/More-Compounds-Failing-Phase-I/
2. Peltz G. 2013. Can 'humanized' mice improve drug development in the 21st century? Trends Pharmacol. Sci. 34:255-60
3. Williams JA, Andersson T, Andersson TB, Blanchard R, Behm MO, et al. 2008. PhRMA white paper on ADME pharmacogenomics. J. Clin. Pharmacol. 48:849-89
4. Anderson S, Luffer-Atlas D, Knadler MP. 2009. Predicting circulating human metabolites: How good are we? Chem. Res. Toxicol. 22:243-56
5. Walker D, Brady J, Dalvie D, Davis J, Dowty M, et al. 2009. A holistic strategy for characterizing the safety of metabolites through drug discovery and development. Chem. Res. Toxicol. 22:1653-62
6. Leclercq L, Cuyckens F, Mannens GS, de Vries R, Timmerman P, Evans DC. 2009. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development. Chem. Res. Toxicol. 22:280-93
7. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, et al. 2002. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann. Intern. Med. 137:947-54
8. Watkins PB, Seeff LB. 2006. Drug-induced liver injury: summary of a single topic clinical research conference. Hepatology 43:618-31
9. Olson H, Betton G, Robinson D, Thomas K, Monro A, et al. 2000. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharmacol. 32:56-67
10. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, et al. 1995. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N. Engl. J. Med. 333:1099-105
11. Manning FJ, Swartz MN, eds. 1995. Review of the Fialuridine (FIAU) Clinical Trials. Washington, DC: Natl. Acad.
12. Regev A. 2014. Drug-induced liver injury and drug development: industry perspective. Semin. Liver Dis. 34:227-39
13. Avigan MI. 2014. DILI and drug development: A regulatory perspective. Semin. Liver Dis. 34:215-26
14. Sandgren EP, Palmiter RD, Heckel JL, Daugherty CC, Brinster RL, Degen JL. 1991. Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell 66:245-56
15. Tateno C, Yoshizane Y, Saito N, Kataoka M, Utoh R, et al. 2004. Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am. J. Pathol. 165:901-12
16. Azuma H, Paulk N, Ranade A, Dorrell C, Al-Dhalimy M, et al. 2007. Robust expansion of human hepatocytes in Fah//Rag2//Il2rg/mice. Nat. Biotechnol. 25:903-10
17. Cederbaum SD, Scott CR, WilcoxWR. 1997. Amino acid metabolism. In Principles and Practice of Medical Genetics, Vol. 2, ed. DL Rimoin, JMConnor, RE Pyeritz, pp. 1872-75. New York: Churchill Livingstone
18. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, et al. 2002. NOD/SCID/null c mouse: An excellent recipient mouse model for engraftment of human cells. Blood 100:3175-82
19. Hasegawa M, Kawai K, Mitsui T, Taniguchi K, Monnai M, et al. 2011. The reconstituted 'humanized liver' in TK-NOG mice is mature and functional. Biochem. Biophys. Res. Commun. 405:405-10
20. Chen AA, Thomas DK, Ong LL, Schwartz RE, Golub TR, Bhatia SN. 2011. Humanized mice with ectopic artificial liver tissues. PNAS 108:11842-47
21. KatohM, Yokoi T. 2007. Application of chimeric mice with humanized liver for predictive ADME. Drug Metab. Rev. 39:145-57
22. Katoh M, Sawada T, Soeno Y, Nakajima M, Tateno C, et al. 2007. In vivo drug metabolism model for human cytochrome P450 enzyme using chimeric mice with humanized liver. J. Pharm. Sci. 96:428-37
23. Lootens L, Van Eenoo P,Meuleman P, Leroux-RoelsG,Delbeke FT. 2009. The uPA(+/+)-SCID mouse with humanized liver as a model for in vivo metabolism of 4-androstene-3,17-dione. Drug Metab. Dispos. 37:2367-74
24. Pozo OJ, Van Eenoo P, Deventer K, Lootens L, Grimalt S, et al. 2009. Detection and structural investigation of metabolites of stanozolol in human urine by liquid chromatography tandem mass spectrometry. Steroids 74:837-52
25. Kamimura H, Nakada N, Suzuki K, Mera A, Souda K, et al. 2010. Assessment of chimeric mice with humanized liver as a tool for predicting circulating human metabolites. Drug Metab. Pharmacokinet. 25:223-35
26. Sanoh S,Horiguchi A, Sugihara K, Kotake Y, Tayama Y, et al. 2012. Prediction of in vivo hepatic clearance and half-life of drug candidates in human using chimeric mice with humanized liver. Drug Metab. Dispos. 40:322-28
27. Sanoh S, Horiguchi A, Sugihara K, Kotake Y, Tayama Y, et al. 2012. Predictability of metabolism of ibuprofen and naproxen using chimeric mice with human hepatocytes. Drug Metab. Dispos. 40:2267-72
28. De Serres M, Bowers G, Boyle G, Beaumont C, Castellino S, et al. 2011. Evaluation of a chimeric (uPA+/+)/SCID mouse model with a humanized liver for prediction of human metabolism. Xenobiotica 41:464-75
29. Nishimura T,Hu Y,WuM, Pham E, Suemizu H, et al. 2013. Using chimeric mice with humanized livers to predict human drug metabolism and a drug-drug interaction. J. Pharmacol. Exp. Ther. 344:388-98
30. Smith DA, Obach RS. 2009. Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem. Res. Toxicol. 22:267-79
31. Guengerich FP, MacDonald JS. 2007. Applying mechanisms of chemical toxicity to predict drug safety. Chem. Res. Toxicol. 20:344-69
32. OkumuraH, Katoh M, Sawada T, Nakajima M, Soeno Y, et al. 2007. Humanization of excretory pathway in chimeric mice with humanized liver. Toxicol. Sci. 97:533-38
33. Xu D, Wu M, Nishimura S, Nishimura T, Michie SA, et al. 2015. Chimeric TK-NOG mice: A predictive model for cholestatic human liver toxicity. J. Pharm. Exp. Ther. 352:274-80
34. van Giersbergen PL, Treiber A, Schneiter R, Dietrich H, Dingemanse J. 2007. Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects. Clin. Pharmacol. Ther. 81:414-19
35. Treiber A, Schneiter R, Häusler S, Stieger B. 2007. Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab. Dispos. 35:1400-7
36. Xu D, Nishimura T, Nishimura S, Zhang H, Zheng M, et al. 2014. Fialuridine induces acute liver failure in chimeric TK-NOG mice: A model for detecting hepatic drug toxicity prior to human testing. PLOS Med. 11:e1001628
37. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, et al. 2013. Sofosbuvir for previously untreated chronic hepatitis C infection. N. Engl. J. Med. 368:1878-87
38. Rubin LJ, BadeschDB, Barst RJ, Galie N, Black CM, et al. 2002. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346:896-903
39. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, et al. 2001. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clin. Pharmacol. Ther. 69:223-31
40. Humbert M, Segal ES, Kiely DG, Carlsen J, Schwierin B, Hoeper MM. 2007. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur. Respir. J. 30:338-44
41. Trusheim MR, Burgess B, Hu SX, Long T, Averbuch SD, et al. 2011. Quantifying factors for the success of stratified medicine. Nat. Rev. Drug Discov. 10:817-33
42. Guo Y, Shafer S,Weller P, Usuka J, Peltz G. 2005. Pharmacogenomics and drug development. Pharmacogenomics 6:857-64
43. Weinshilboum R, Wang L. 2004. Pharmacogenomics: bench to bedside. Nat. Rev. Drug Discov. 3:739-48
44. Hu Y, Wu M, Nishimura T, Zheng M, Peltz G. 2013. Human pharmacogenetic analysis in chimeric mice with 'humanized livers. ' Pharmacogenet. Genomics 23:78-83
45. Zhou HH. 2001. CYP2C19 genotype determines enzyme activity and inducibility of S-mephenytoin hydroxylase. Clin. Chim. Acta 313:203-8
46. Desta Z, Zhao X, Shin JG, Flockhart DA. 2002. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin. Pharmacokinet. 41:913-58
47. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, et al. 2011. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther. 90:328-32
48. Pirmohamed M, Park BK. 2003. Cytochrome P450 enzyme polymorphisms and adverse drug reactions. Toxicology 192:23-32
49. Lee CR, Goldstein JA, Pieper JA. 2002. Cytochrome P450 2C9 polymorphisms: A comprehensive review of the in-vitro and human data. Pharmacogenetics 12:251-63
50. Dorado P, Berecz R, Norberto MJ, Yasar U, Dahl ML,Llerena A. 2003. CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers. Eur. J. Clin. Pharmacol. 59:221-25
51. Xu D, Nishimura T, Zheng M, WooM, SuH, et al. 2014. Enabling autologous human liver regeneration with differentiated adipocyte stem cells. Cell Transplant. 23:1573-84
52. Bissig K-D, Wieland SF, Tran P, Isogawa M, Le TT, et al. 2010. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J. Clin. Investig. 120:650-53
53. Ohara E, Hiraga N, Imamura M, Iwao E, Kamiya N, et al. 2011. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice. J. Hepatol. 54:872-78
54. Zhang L, Reynolds KS, Zhao P, Huang SM. 2010. Drug interactions evaluation: An integrated part of risk assessment of therapeutics. Toxicol. Appl. Pharmacol. 243:134-45
55. Bode C. 2010. The nasty surprise of a complex drug-drug interaction. Drug Discov. Today 15:391-95
56. vanHerwaarden AE, Wagenaar E, van der Kruijssen CMM, vanWaterschoot RAB, Smit JW, et al. 2007. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J. Clin. Investig. 117:3583-92
57. vanWaterschoot RAB, vanHerwaardenAE, Lagas JS, SparidansRW,Wagenaar E, et al. 2008. Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes. Mol. Pharmacol. 73:1029-36
58. Nelson DR, Zeldin DC, Hoffman SMG, Maltais LJ, Wain HM, Nebert DW. 2004. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14:1-18
59. Guo YY, Weller PF, Farrell E, Cheung P, Fitch B, et al. 2006. In silico pharmacogenetics: warfarin metabolism. Nat. Biotechnol. 24:531-36
60. Hersman EM, Bumpus NN. 2014. A targeted proteomics approach for profilingmurine cytochrome P450 expression. J. Pharmacol. Exp. Ther. 349:221-28
61. Crystal AS, Shaw AT, Sequist LV, Friboulet L, Niederst MJ, et al. 2014. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science 346:1480-86
62. Nagamoto Y, Takayama K, Tashiro K, Tateno C, Sakurai F, et al. 2014. Efficient engraftment of human iPS cell-derived hepatocyte-like cells in uPA/SCIDmice by overexpression of FNK, a Bcl-xL mutant gene. Cell Transplant. 24:1127-38